

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

VOLUNTARY ANNOUNCEMENT

PROPOSED ON-MARKET SHARE REPURCHASE

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated June 27, 2023 in relation to, among others, the general mandate to repurchase (the “**Repurchase Mandate**”) shares of the Company (the “**Shares**”) granted by the shareholders of the Company (the “**Shareholders**”) at the annual general meeting of the Company held on June 27, 2023 (the “**AGM**”).

Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 424,841,176 Shares, being 10% of the total number of issued Shares as at the date of the AGM, on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). The board of directors (the “**Board**”) of the Company hereby announces that, on December 5, 2023, it has resolved to utilize the Repurchase Mandate to repurchase Shares in the open market from time to time at an aggregate price up to US\$600 million (the “**Proposed Share Repurchase**”).

The Company believes that the current trading price of the Shares does not reflect their intrinsic value or the actual business prospects of the Company, and the Proposed Share Repurchase will demonstrate the Company’s confidence in its own business outlook and prospects. The Company is also of the view that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase, while maintaining a solid financial position.

The Company will conduct the Proposed Share Repurchase in strict compliance with the memorandum and articles of association of the Company, the Rules Governing the Listing of Securities on the Stock Exchange, the Codes on Takeovers and Mergers and Share Buy-backs, the Companies Act of the Cayman Islands and other applicable laws and regulations.

Shareholders and potential investors of the Company should note that any exercise of the Repurchase Mandate by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any Share repurchases or whether or not the Company will make any repurchase at all. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, December 6, 2023

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Kenneth Walton Hitchner III, Mr. Jackson Peter Tai and Dr. Jue Chen as independent non-executive Directors.

* *For identification purpose only*